The Technical Analyst
Select Language :
Zogenix Inc [ZGNX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Zogenix Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Zogenix Inc is listed at the  Exchange

0.00% $26.68

America/New_York / 31 des 1970 @ 19:00


RATING 2022-03-18
B
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Buy
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/204/201/212/213/214/21
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -6.56 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-1.12x
Company: PE -6.56 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 26.08 - 27.28

( +/- 2.26%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2022-03-07 Breitmeyer James B Sell 1 250 Common Stock
2022-03-07 Breitmeyer James B Sell 9 375 Stock Option (Right to Buy)
2022-03-07 Breitmeyer James B Sell 6 250 Stock Option (Right to Buy)
2022-03-07 Breitmeyer James B Sell 9 000 Stock Option (Right to Buy)
2022-03-07 Breitmeyer James B Sell 10 000 Stock Option (Right to Buy)
INSIDER POWER
0.00
Last 100 transactions
Buy: 446 833 | Sell: 2 096 567

Forecast: 01:40 - $25.85

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $26.68 (0.00% )
Volume 11.25 mill
Avg. Vol. 3.10 mill
% of Avg. Vol 363.20 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Zogenix Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Zogenix Inc

RSI

Intraday RSI14 chart for Zogenix Inc

Last 10 Buy & Sell Signals For ZGNX

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Zogenix Inc

ZGNX

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.

Last 10 Buy Signals

Date Signal @
TRMBMar 28 - 12:26$63.32
OSHIUSDMar 28 - 12:2494.91
AGIXUSDMar 28 - 12:241.405
VRNSMar 28 - 12:24$48.21
ACMRMar 28 - 12:24$28.90
TSLQMar 28 - 12:2237.98
FTAIMar 28 - 12:22$67.14
INTCMar 28 - 12:22$44.29
EXPEMar 28 - 12:22$138.29
REGMar 28 - 12:20$60.38

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.